Denali Therapeutics Inc.
Developing BBB-crossing biotherapeutics for lysosomal storage and neurodegenerative diseases; AVLAYAH launched in 2026.
Rare disease & neurodegeneration · Blood-brain-barrier TransportVehicle biologics · Commercial + clinical